Sorrento and Celularity to initiate emergency allogeneic natural killer cell therapy development for Coronavirus infection
On Jan. 29, 2020, Sorrento announced it had produced a preclinical batch of the STI-4398 (COVIDTRAP) protein to immediately commence testing its neutralization and blocking activity in preventing SARS-CoV-2 virus from infecting ACE2-expressing cells.
Tags:
Source: NASDAQ
Credit:
